NanoViricides Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387

NanoViricides, Inc. filed its Form 10-Q for the quarter ended September 30, 2025, detailing significant progress on NV-387, a first-in-class broad-spectrum antiviral candidate designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses. The company noted that NV-387's unique mechanism may address major unmet needs across multiple viral diseases, including influenza strains prone to rapid resistance, RSV, measles, MPox, and gaps in existing smallpox countermeasures. This development comes at a critical time when current antiviral solutions face challenges with evolving viral threats.

The company highlighted current concerns such as the dominant A/H3N2 clade K variant and a mismatched seasonal vaccine with historically low efficacy, underscoring the urgent need for antiviral solutions that do not lose effectiveness as viruses evolve. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, with plans to develop it as a treatment for RSV, COVID, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox infections. The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as detailed in their corporate information available at https://www.nanoviricides.com.

NanoViricides holds a worldwide exclusive perpetual license to TheraCour nanomedicine technology for several drugs with specific targeting mechanisms for the treatment of numerous human viral diseases, including Human Immunodeficiency Virus, Hepatitis B and C viruses, rabies, herpes simplex viruses, influenza, dengue viruses, Ebola/Marburg viruses, and certain coronaviruses. The company intends to obtain additional licenses for RSV, poxviruses, and/or enteroviruses if initial research proves successful. As with any drug development efforts, the company notes that the path to typical drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development.

The latest news and updates relating to NanoViricides are available through various financial news platforms, including the specialized communications platform that published this announcement at https://www.InvestorWire.com. The company's platform technology and programs are based on the TheraCour nanomedicine technology, which represents a novel approach to antiviral therapy through special purpose nanomaterials designed to combat viral infections more effectively than traditional antiviral medications.